Selenium nanoparticles coated with pH responsive silk fibroin complex for fingolimod release and enhanced targeting in thyroid cancer

References

• Carty S, Cooper D, Doherty G, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid. 2009;19(11):1153–1158.
   PubMed Web of Science ®Google Scholar
• Vaccarella S, Dal Maso L, Laversanne M, et al. The impact of diagnostic changes on the rise in thyroid cancer incidence: a population-based study in selected high-resource countries. Thyroid. 2015;25(10):1127–1136.
   PubMed Web of Science ®Google Scholar
• Cabanillas M, McFadden D, Durante C. Thyroid cancer. Lancet. 2016;388(10061):2783–2795.
   PubMed Web of Science ®Google Scholar
• Xing M, Haugen B, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381(9871):1058–1069.
   PubMed Web of Science ®Google Scholar
• Kim T, Kim Y, Kim H, et al. Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma. Oral Oncol. 2017;71:81–86.
   PubMed Web of Science ®Google Scholar
• Da Silva C, Rueda F, Löwik C, et al. Combinatorial prospects of nano-targeted chemoimmunotherapy. Biomaterials. 2016;83:308–320.
   PubMed Web of Science ®Google Scholar
• Farrell D, Alper J, Ptak K, et al. Recent advances from the National Cancer Institute Alliance for Nanotechnology in Cancer. ACS Nano. 2010;4(2):589–594.
   PubMed Web of Science ®Google Scholar
• Mehrotra S, Chouhan D, Konwarh R, et al. Comprehensive review on silk at nanoscale for regenerative medicine and allied applications. ACS Biomater Sci Eng. 2019;5(5):2054–2078.
   PubMed Web of Science ®Google Scholar
• Wani S, Veerabhadrappa G. Silk fibroin based drug delivery applications: promises and challenges. Curr Drug Targets. 2018;19(10):1177–1190.
   PubMed Web of Science ®Google Scholar
• Crivelli B, Perteghella S, Bari E, et al. Silk nanoparticles: from inert supports to bioactive natural carriers for drug delivery. Soft Matter. 2018;14(4):546–557.
   PubMed Web of Science ®Google Scholar
• Liu W, Li X, Wong Y, et al. Selenium nanoparticles as a carrier of 5-fluorouracil to achieve anticancer synergism. ACS Nano. 2012;6(8):6578–6591.
   PubMed Web of Science ®Google Scholar
• Huang Y, He L, Liu W, et al. Selective cellular uptake and induction of apoptosis of cancer-targeted selenium nanoparticles. Biomaterials. 2013;34(29):7106–7116.
   PubMed Web of Science ®Google Scholar
• Fu X, Yang Y, Li X, et al. RGD peptide-conjugated selenium nanoparticles: antiangiogenesis by suppressing VEGF-VEGFR2-ERK/AKT pathway. Nanomedicine. 2016;12(6):1627–1639.
   PubMed Web of Science ®Google Scholar
• Yu Q, Liu Y, Cao C, et al. The use of pH-sensitive functional selenium nanoparticles shows enhanced in vivo VEGF-siRNA silencing and fluorescence imaging. Nanoscale. 2014;6(15):9279–9292.
   PubMed Web of Science ®Google Scholar
• Chen Q, Yu Q, Liu Y, et al. Multifunctional selenium nanoparticles: chiral selectivity of delivering MDR-siRNA for reversal of multidrug resistance and real-time biofluorescence imaging. Nanomedicine. 2015;11(7):1773–1784.
   PubMed Web of Science ®Google Scholar
• Zakharia Y, Bhattacharya A, Rustum Y. Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development. Oncotarget. 2018;9(12):10765–10783.
   PubMedGoogle Scholar
• Miao Q, Xu J, Lin A, et al. Recent advances for the synthesis of selenium-containing small molecules as potent antitumor agents. Curr Med Chem. 2018;25(17):2009–2033.
   PubMed Web of Science ®Google Scholar
• Lee J, Engler J, Collawn J, et al. Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur J Biochem. 2001;268(7):2004–2012.
   PubMedGoogle Scholar
• Han L, Huang R, Liu S, et al. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Mol Pharm. 2010;7(6):2156–2165.
   PubMed Web of Science ®Google Scholar
• Du W, Fan Y, He B, et al. Bionano interactions of mcf-7 breast tumor cells with a transferrin receptor targeted nanoparticle. Mol Pharm. 2015;12(5):1467–1476.
   PubMed Web of Science ®Google Scholar
• Keer H, Kozlowski J, Tsai Y, et al. Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo. J Urol. 1990;143(2):381–385.
   PubMed Web of Science ®Google Scholar
• Liang M, Gao C, Wang Y, et al. Enhanced blood-brain barrier penetration and glioma therapy mediated by T7 peptide-modified low-density lipoprotein particles. Drug Deliv. 2018;25(1):1652–1663.
   PubMed Web of Science ®Google Scholar
• Yu M, Pang W, Yang T, et al. Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer. Eur J Pharm Sci. 2016;92:39–48.
   PubMed Web of Science ®Google Scholar
• Riaz M, Zhang X, Wong K, et al. Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy. IJN. 2019;14:2879–2902.
   Web of Science ®Google Scholar
• Lu Y, Jiang W, Wu X, et al. Peptide T7-modified polypeptide with disulfide bonds for targeted delivery of plasmid DNA for gene therapy of prostate cancer. Int J Nanomedicine. 2018;13:6913–6927.
   PubMed Web of Science ®Google Scholar
• Magro G, Cataldo I, Amico P, et al. Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target. Thyroid. 2011;21(3):267–277.
   PubMed Web of Science ®Google Scholar
• Wang R, Hu Y, Yang Y, et al. Using PEGylated iron oxide nanoparticles with ultrahigh relaxivity for MR imaging of an orthotopic model of human hepatocellular carcinoma. J Nanopart Res. 2017;19(2):12.
   Web of Science ®Google Scholar
• Tonelli F, Lim K, Loveridge C, et al. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal. 2010;22(10):1536–1542.
   PubMed Web of Science ®Google Scholar
• Huwiler A, Zangemeister-Wittke U. The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: recent findings and new perspectives. Pharmacol Ther. 2018;185:34–49.
   PubMed Web of Science ®Google Scholar
• Nagahashi M, Yamada A, Katsuta E, et al. Targeting the SphK1/S1P/S1PR1 axis that links obesity, chronic inflammation, and breast cancer metastasis. Cancer Res. 2018;78(7):1713–1725.
   PubMed Web of Science ®Google Scholar
• Oaks J, Santhanam R, Walker C, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 2013;122(11):1923–1934.
   PubMed Web of Science ®Google Scholar
• Azuma H, Takahara S, Horie S, et al. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol. 2003;169(6):2372–2377.
   PubMed Web of Science ®Google Scholar
• Huang X, Liang H, Li Z, et al. Monodisperse phase transfer and surface bioengineering of metal nanoparticles via a silk fibroin protein corona. Nanoscale. 2017;9(8):2695–2700.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang J, Zhang L. Creation of highly stable selenium nanoparticles capped with hyperbranched polysaccharide in water. Langmuir. 2010;26(22):17617–17623.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhou X, Yu Q, et al. Epigallocatechin-3-gallate (EGCG)-stabilized selenium nanoparticles coated with Tet-1 peptide to reduce amyloid-β aggregation and cytotoxicity. ACS Appl Mater Interfaces. 2014;6(11):8475–8487.
   PubMed Web of Science ®Google Scholar
• Yin T, Yang L, Liu Y, et al. Sialic acid (SA)-modified selenium nanoparticles coated with a high blood-brain barrier permeability peptide-B6 peptide for potential use in Alzheimer's disease. Acta Biomater. 2015;25:172–183.
   PubMed Web of Science ®Google Scholar
• Long X, Zhang Z, Han S, et al. Structural mediation on polycation nanoparticles by sulfadiazine to enhance DNA transfection efficiency and reduce toxicity. ACS Appl Mater Interfaces. 2015;7(14):7542–7551.
   PubMed Web of Science ®Google Scholar
• Zhang X, Lin C, Lu A, et al. Liposomes equipped with cell penetrating peptide BR2 enhances chemotherapeutic effects of cantharidin against hepatocellular carcinoma. Drug Deliv. 2017;24(1):986–998.
   PubMed Web of Science ®Google Scholar
• Tahmasbi R, Chen C, Aresh W, et al. Combinational effects of active targeting, shape, and enhanced permeability and retention for cancer theranostic nanocarriers. ACS Appl Mater Interfaces. 2019;11(11):10505–10519.
   PubMed Web of Science ®Google Scholar
• Shim M, Park J, Yoon H, et al. Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy. J Control Release. 2019;294:376–389.
   PubMed Web of Science ®Google Scholar
• Azuma H, Takahara S, Ichimaru N, et al. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res. 2002;62(5):1410–1419.
   PubMed Web of Science ®Google Scholar
• Chua C, Lee D, Ling M, et al. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int J Cancer. 2005;117(6):1039–1048.
   PubMed Web of Science ®Google Scholar
• Schmid G, Guba M, Papyan A, et al. FTY720 inhibits tumor growth and angiogenesis. Transplant Proc. 2005;37(1):110–111.
   PubMed Web of Science ®Google Scholar
• Lee T, Man K, Ho J, et al. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis. 2004;25(12):2397–2405.
   PubMed Web of Science ®Google Scholar
• Hung J, Lu Y, Wang Y, et al. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res. 2008;68(4):1204–1212.
   PubMed Web of Science ®Google Scholar
• Kalhori V, Magnusson M, Asghar M, et al. FTY720 (Fingolimod) attenuates basal and sphingosine-1-phosphate-evoked thyroid cancer cell invasion. Endocr Relat Cancer. 2016;23(5):457–468.
   PubMed Web of Science ®Google Scholar
• Shi F, Cao X, Hu Z, et al. Pleiotropic FTY720 is a specific and potent therapy for hypertrophic scars. J Invest Dermatol. 2017;137(7):1552–1561.
   PubMed Web of Science ®Google Scholar
• Guo X, Chen J, Zeng B, et al. Ultrasound-mediated delivery of RGD-conjugated nanobubbles loaded with fingolimod and superparamagnetic iron oxide nanoparticles: targeting hepatocellular carcinoma and enhancing magnetic resonance imaging. RSC Adv. 2020;10(64):39348–39358.
   PubMed Web of Science ®Google Scholar